Stocktoria
STRATA Skin Sciences, Inc. SSKN
OTC · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2005-10-28
STRATA Skin Sciences, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.7M | $33.6M | $33.4M | $36.2M | $30.0M | $23.1M | $31.6M | $29.9M | $31.8M | $30.7M |
| Gross profit | $17.9M | $19.2M | $18.5M | $21.8M | $19.9M | $14.1M | $20.3M | $17.1M | $18.8M | $18.1M |
| R&D expense | $421,000 | $883,000 | $1.3M | $1.0M | $1.4M | $1.3M | $1.0M | $1.1M | $1.7M | $1.9M |
| Operating income | -$4.7M | -$9.3M | -$8.6M | -$4.6M | -$4.4M | -$4.1M | -$3.0M | -$3.4M | -$1.8M | -$3.6M |
| Interest expense | — | — | $1.6M | $926,000 | $314,000 | $211,000 | $515,000 | $1.1M | $3.2M | $4.9M |
| Income tax | $12,000 | -$170,000 | -$92,000 | $63,000 | $34,000 | $275,000 | -$149,000 | -$264,000 | $129,000 | $255,000 |
| Net income | -$6.3M | -$10.1M | -$10.8M | -$5.5M | -$2.7M | -$4.4M | -$3.8M | -$4.0M | -$21.5M | -$3.3M |
| EPS (diluted) | $-1.35 | $-2.65 | $-3.10 | $-0.16 | — | $-0.13 | $-0.11 | $-0.15 | $-3.26 | $-3.77 |
| Operating cash flow | -$2.8M | $188,000 | -$519,000 | -$924,000 | $1.5M | $2.1M | $2.2M | $2.9M | $4.1M | $322,000 |
| Free cash flow | -$4.3M | -$1.4M | -$5.5M | -$4.7M | -$2.1M | -$63,000 | $2.1M | — | — | — |
| Cash & equivalents | $7.9M | $7.3M | $6.8M | $5.4M | $12.6M | $10.6M | $8.1M | $16.5M | $4.1M | $3.9M |
| Inventory | $2.8M | $2.2M | $2.7M | $3.1M | $3.5M | $3.4M | $3.0M | $2.8M | $3.0M | $2.8M |
| Total assets | $30.5M | $34.9M | $42.0M | $52.3M | $46.6M | $46.8M | $47.3M | $47.5M | $39.1M | $43.2M |
| Total liabilities | $27.6M | $30.0M | $29.3M | $30.4M | $21.2M | $20.9M | $18.7M | $16.3M | $19.3M | $28.2M |
| Shareholders' equity | $2.9M | $5.0M | $12.7M | $21.8M | $25.4M | $25.9M | $28.7M | $31.2M | $19.9M | $15.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -8.5% | +0.6% | -7.8% | +20.6% | +29.8% | -26.9% | +5.8% | -6.0% | +3.4% | +66.0% |
| Free cash flow growth | — | — | — | — | — | -103.0% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001051514 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.